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Thromboxane receptorWe have investigated the presence of thromboxane A2 (TXA2) receptor associated with lipid rafts in
human platelets and the regulation of platelet function in response to TXA2 receptor agonists when
lipid rafts are disrupted by cholesterol extraction. Platelet aggregation with TXA2 analogs U46619
and IBOP was almost blunted in cholesterol-depleted platelets, as well as aIIbb3 integrin activation
and P-selectin exposure. Raft disruption also inhibited TXA2-induced cytosolic calcium increase
and nucleotide release, ruling out an implication of P2Y12 receptor. An important proportion of
TXA2 receptor (40%) was colocalized at lipid rafts. The presence of the TXA2 receptor associated with
lipid rafts in platelets is important for functional platelet responses to TXA2.
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The inhibition of platelet thromboxane A2 (TXA2) synthesis by
aspirin constitutes the ﬁrst front of antiplatelet treatment in
patients with acute cardiovascular disease and, in secondary pre-
vention, to reduce the risk of a new event among patients at high
risk of occlusive vascular events [1]. TXA2 is produced by activated
platelets and acts by reinforcing platelet activation and by inducing
the recruitment of new platelets to the growing thrombus. In addi-
tion, TXA2 is a powerful vasoconstrictor. Actions of TXA2 on plate-
lets are mediated by the activation of TXA2 receptor in the
membrane of cells. The TXA2 receptor belongs to the superfamily
of seven transmembrane-domains receptors. In platelets, two iso-
forms of TXA2 receptor (TPa and TPb) have been identiﬁed [2]. Both
the TPa and TPb subtypes mediate the stimulation of phospholipase
C and an increase in intracellular concentrations of inositol 1,4,5-
triphosphate and diacylglycerol. The formation of inositol 1,4,5-tri-
phosphate induces an increase in the cytosolic concentration of
Ca2+, whereas the release of diacylglycerol activates PKC [2]. These
actions of the TXA2 receptors in platelets are mediated by the
association of the receptor to Gq and G13 proteins [3].The cell membrane microdomains called lipid rafts are sphingo-
lipid and cholesterol-based structures consisting of very small
domains (20–50 nm) of tightly packed lipids displaying lateral
mobility [4]. Lipid raft formation should therefore be facilitated
in membranes rich in cholesterol and sphingolipids that promote
the formation of liquid-ordered domains in the presence of
cholesterol [5]. Interestingly, there is a relatively high amount of
sphingomyelin in human platelets plasma membrane as compared
to other cell types, suggesting a lipid composition in favor of lipid
raft formation in these cells [6]. Several previous studies have
suggested that lipid rafts are highly dynamic platelet membrane
structures involved in critical signaling mechanisms [4,7]. It has
been reported that the presence of different proteins associated
with lipid rafts, including membrane receptors (CD36, GPIb, GPVI,
P2Y12), signal transduction partners (LAT, src, G proteins) and
enzymes (PI3K, PLCc2) [6]. However, to the best of our knowledge,
the presence of TXA2 receptor in lipid rafts in platelets has not been
previously described, although in other cell types the localization
of TXA2 receptors in lipid rafts have already been demonstrated
[8,9].
The aim of this study was to explore the association of the TXA2
receptor with lipid rafts in human platelets and the functional
implications of this location for the platelet responses to TXA2.
Our results demonstrate, for the ﬁrst time, the importance of lipid
rafts for TXA2-induced platelet responses, a process related with
the presence of a fraction of TXA2 receptors associated with lipid
rafts.
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2.1. Antibodies
TXA2 receptor (Cayman Chemicals, Ann Harbor, MI); CD36
(Santa Cruz Biotechnology, Dallas, TX); CD62-FITC, CD61-PE,
CD42-phycoerythrin (PE) (Beckman Coulter, Barcelona, Spain);
PAC-1-ﬂuorescein isothiocyanate (FITC) (Becton Dickinson,
Madrid, Spain).
2.2. Blood collection and platelet processing
Venous blood was obtained from healthy fasting donors, drug-
free for at least 15 days, after informed consent, as approved by
the institutional review board of the Hospital La Fe. Platelet isola-
tion and washing were performed as described [10]. After washing,
platelets were re-suspended in HBSS buffer (in mmol/L): 0.8
MgSO4, 5.36 KCl, 0.441 KH2PO4, 137 NaCl, 0.34 Na2HPO4, 5.55
Glucose, 20 HEPES, pH 7.4.
2.3. Depletion of platelet cholesterol
Platelet rich plasma (PRP) was incubated (15 min., 37 C) with
5 mM methyl-b-cyclodextrin (MbCD) (Sigma Aldrich, Madrid,
Spain) [11]. Platelets were then isolated and re-suspended as
described [10].
2.4. Platelet aggregation
Platelet aggregation was assessed by optical aggregometry in
300 ll of washed platelets (2  108 platelets/ml) in HBSS buffer
supplemented with 1 mM CaCl2 (ﬁnal concentration) at 37 C with
constant stirring (1000 rpm) in a Chrono-Log 490–2D platelet
aggregometer (Chrono-Log Corporation, Havertown, PA). The
amplitude (percentage) of the platelet aggregation response was
monitored up to 3 min. in reference to a buffer blank.
2.5. Dense granules release
Dense granules release was monitored by platelet nucleotide
release as previously described [12]. Brieﬂy, after 3 min. of platelet
aggregation, samples were transferred to an eppendorf tube and
centrifuged (1 min., 13000g), and the supernatant was collected.
Perchloric acid (1:10 v/v, ﬁnal concentration 0.3 N) was added to
supernatants, kept in ice for 1 h, and the precipitated proteins were
pelleted by centrifugation (8 min., 13000g, 4 C). Supernatants
were carefully neutralized with KOH, centrifuged (8 min.,
13000g, 4 C), and kept at 80 C until further processing.
Thawed samples were ﬁltrated and injected in a Waters 600E HPLC
system equipped with a C18 column (Teknokroma, Barcelona,
Spain) and a UV detector Waters 486. Isocratic elution (0.4 ml/
min., 30 C) was performed with a mobile phase consisting of
200 mmol/L KH2PO4 adjusted to pH 6 with NH4OH. Nucleotide
elution was monitored at 254 nm (Lambda-Max Model 480,
Waters–Waters Cromatografía SA, Barcelona, Spain). Concentra-
tion of nucleotides was calculated using a standard calibration
curve of adenine nucleotides.
2.6. Flow cytometry
MbCD-free or MbCD-treated washed platelets (2  108 plate-
lets/ml) in HBSS buffer plus 1 mmol/L CaCl2 were incubated with-
out stirring (10 min., 37 C). Agonists were added, and incubation
was continued for 5 min. without stirring. Duplicate 10-lL aliquots
of stimulated platelets were transferred to polypropylene tubesthat contained 100 lL HBSS buffer without calcium. To each sam-
ple, saturating concentrations of PAC-1-FITC or CD62-FITC plus a
general platelet marker (CD42-PE for PAC-1 or CD61-PE for CD62
analysis) were added, kept undisturbed (30 min., 20 C, dark),
quench-diluted with 1 ml ice-cold HBSS, and maintained at 4 C
in the dark [10]. Platelets were gated based on size and
CD42/CD61 ﬂuorescence. Results are reported as percentages of
platelets expressing PAC-1 or CD62 in a total of 5000 platelets
per sample analyzed in an EPICS XL-MCL ﬂow cytometer (Beckman
Coulter, Madrid, Spain).
2.7. Measurement of cytosolic free Ca2+ concentration
PRP (treated or not with MbCD) was incubated with 1.5 lM
FURA 2/AM (37 C, 45 min.), washed and resuspended in HBSS buf-
fer (75  105 platelet/ml) containing 1 mM calcium. Changes in
FURA 2/AM ﬂuorescence were continuously monitored after ago-
nist addition by dual excitation ﬂuorimetry at 340 and 380 nm,
at 37 C with stirring in an RF-1501 spectroﬂuorophotometer
(Shimadzu, Duisburg, Germany), and the calcium concentration
was calculated as described [13].
Isolation of lipid rafts fractions and identiﬁcation of associated
proteins was performed as previously described [14]. Washed
platelets (4  108 platelets/ml) were lysed on ice with lysis buffer
(ﬁnal concentration (in mmol/L): 50 Tris–HCl pH 7.4, 100 NaCl, 5
EDTA, 50 NaF, 10 sodium pyrophosphate, 1 Na3VO4, 1% CHAPS sup-
plemented with 1 protease inhibitor cocktail III (Merck
Chemicals Ltd, Nottingham, UK). After complete rupture of plate-
lets by aspirating repeatedly with a Hamilton syringe, lysates were
mixed 1:1 with MNE buffer (MES (2-(N-morpholino) ethanesulfo-
nic acid) 25 mmol/L pH 6.5, EDTA 5 mmol/L, NaCl 150 mmol/L)
containing 80% sucrose. 1.5 ml of this mixture was laid on the bot-
tom of an ultracentrifuge tube and sequencially overlaid carefully
with 1.5 ml of 30% and 750 ll of 5% sucrose in MNE buffer. Samples
were centrifuged (200000g, 18 h, 4 C). Aliquots of 300 ll were
carefully collected sequentially from the upper surface, mixed
1:1 with Laemmli sample buffer, and boiled 5 min. Equal volumes
of sample were loaded on 4–12% polyacrylamide preformed gels
(Life Technologies, Madrid, Spain), and the separated proteins were
transferred to nitrocellulose membranes [10]. Immunodetection of
CD36 and TXA2 receptor were performed as previously described
[10]. Images were scanned and quantiﬁed using the freely available
public domain software ImageJ 1.45e (NIH, http:// rsbweb.nih.gov/
ij/).
2.8. Statistical analysis
Signiﬁcance was determined by Student’s t-test. Results were
expressed as mean ± S.E.M. of at least three different experiments.
3. Results
3.1. Regulation of thromboxane-induced platelet activation by the lipid
rafts
To determine whether lipid rafts played a role in thromboxane-
induced platelet activation, we investigated the effect of mem-
brane cholesterol depletion on platelet aggregation, P-selectin
exposure, and aIIbb3 activation. We used two stable, structurally
different analogs of thromboxane: U46619 (1 lM) and IBOP (10
nM) (Cayman Chemicals, Ann Arbor, MI). After cholesterol deple-
tion with MbCD, U46119- and IBOP-induced aggregation were sig-
niﬁcantly inhibited (Fig. 1A). The different patterns of inhibition
could be attributed to the different concentrations of the two
thromboxane analogs. Interestingly, platelet aggregation induced
Fig. 1. Regulation of platelet responses to thromboxane by lipid raft disruption. PRP was treated with 5 mM MbCD (30 min, 37 C) or solvent and platelets washed as
described in Section 2. In (A), MbCD-treated or control platelets (2  108 platelets/mL) were stimulated with 1 lM U46619 or 10 nM IBOP and aggregation recorded up to
3 min. In (B) and (C), control or MbCD-treated platelets (2  107 platelets/mL) were stimulated with U46619 (1 lM) and incubated for 5 min. without stirring. Duplicate
aliquots of stimulated platelets were diluted and incubated with PAC-1-FITC or CD62-FITC plus a general marker of platelets (CD42-PE for PAC-1 or CD61-PE for CD62), and
ﬂow cytometric determinations were performed as described in Methods. Results are media ± S.E.M. of percentage of platelets that bind CD62 or PAC-1 of 5 different
experiments; ⁄P < 0.05. Disruption of lipid rafts inhibited platelet aggregation, aIIbb3 activation and P-selectin exposure in response to U46619.
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collagen) was not affected by cholesterol depletion (results not
shown) suggesting that platelet are functional after MbCD
treatment.
As platelet aggregation is dependent on the activation of aIIbb3,
we used ﬂow cytometry to assay the activation process of this
integrin with the PAC-1 antibody, which speciﬁcally binds the
activated conformation of aIIbb3 [15] in control platelets and in
platelets treated with MbCD. Fig. 1B shows that cholesterol deple-
tion strongly reduced the U46619-induced activation of the aIIbb3
integrin.
We next examined the role of cholesterol depletion on the
release of a-granules by evaluating the exposure of P-selectin in
the surface of platelets by ﬂow cytometry. Results in Fig. 1C shows
that exposure of P-selectin was signiﬁcantly inhibited in choles-
terol-depleted platelets.
3.2. P2Y12-independent platelet responses to thromboxane are
regulated by lipid rafts
It has been previously demonstrated that some platelet
responses to thromboxane stimulation are at least partially depen-
dent on the action of the released ADP upon its receptor P2Y12
[16,17]. In addition, cholesterol depletion has been shown to
reduce ADP-induced platelet aggregation through P2Y12 receptor
due to the presence of P2Y12 [18] and Gi [17] associated with the
lipid rafts. In accordance with this, Fig. 2A shows that blockadeof P2Y12 receptor with 2MeSAMP (10 lM) strongly inhibited
U46619-induced washed platelet aggregation [19,20]. In contrast,
other platelet responses to U46619 stimulation such as dense
granule release (Fig. 2B) and increase in cytosolic calcium
(Fig. 2C) are not signiﬁcantly affected by the blockade of the
P2Y12 receptor in agreement with other authors [21]. Therefore,
we concluded that thromboxane receptor responses are indepen-
dent of P2Y12. Then, we explored the effect of lipid rafts disruption
on these platelets responses to U46619 that are independent of
ADP release and P2Y12 receptor activation (Fig. 2B and C). We
found that MbCD-treatment signiﬁcantly reduced platelet dense
granule release evaluated by measurement of the release of ATP
(Fig. 2D) and cytosolic calcium increase in FURA 2AM loaded plate-
lets in response to U46619 (Fig. 2E). All together, the results in
Figs. 1 and 2 suggested that the association of the thromboxane
receptor with lipid rafts is important for the platelet responses to
the eicosanoid.
3.3. The thromboxane receptor is partially associated with lipid rafts
To address the association of the thromboxane receptor with
lipid rafts, lysed platelets were fractionated by sucrose density cen-
trifugation in order to isolate the low density lipid raft membranes.
The fractions corresponding to lipid rafts were identiﬁed using
Western blotting by the presence of CD36, which is a generally
accepted marker of platelet lipid rafts [22]. Western blotting of
the same fractions showed that the thromboxane receptor was
Fig. 2. Relevance of lipid rafts for thromboxane-induced platelet responses independent of the P2Y12 receptor. In (A), washed platelets were incubated (1 min, 37 C) with
10 lM 2MeSAMP to block the P2Y12 receptor or solvent and then stimulated with 1 lM U46619 and aggregation registered for 3 min. In (B) and (D), platelets incubated with
2MeSAMP (B) or MbCD (D) were stimulated with U46619 (1 lM) for 3 min., centrifuged, and ATP release determined by HPLC as described in Section 2. In (C) and (E), FURA
2AM-loaded platelets were incubated with 2MeSAMP (C) or MbCD (E) and stimulated with U46619 1 lM. Fluorescence was registered for 3 min. and transformed to calcium
concentration as described in Section 2. Data in A are representative of 5 different analyses; data in B through D are media ± SEM of 3 different experiments; ⁄P < 0.05 MbCD-
treated vs. control. Blockade of P2Y12 receptor with 2MeSAMP strongly reduced U46619-induced platelet aggregation but did not affect dense granule release nor calcium
increase, which are, therefore, P2Y12-receptor independent responses. In contrast, disruption of lipid rafts with MbCD signiﬁcantly inhibited these U46619-induced platelet
responses independent of ADP.
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boxane receptor was also present in other fractions not corre-
sponding to lipid rafts. Densitometry of the fractions revealed
that 39.5% of the thromboxane receptor was associated with lipid
rafts (Fig. 3B; fractions 2–4). Furthermore, cholesterol depletion
and lipid rafts disruption caused a redistribution of CD36 and
thromboxane receptor to the heavier gradient fractions (Fig. 3C
and D).
4. Discussion
The results in the present study show that the association of the
thromboxane receptor with lipid rafts is important for platelet
responses to thromboxane A2. This is demonstrated by the
observed inhibition of several platelet responses including plateletFig. 3. Association of TXA2 receptor with lipid rafts. In (A) and (B), control or MbCD-tr
fractions separated and numbered from the upper layer (1–12). In (C) and (D), fractions c
the TXA2 receptor was determined by immunodetection. Images were quantiﬁed fo
representatives of three different experiments. 39.5% of TXA2 receptor was associated waggregation, dense and a-granule release, aIIbb3 activation and the
increase in cytosolic calcium in response to thromboxane analogs
in cholesterol depleted platelets by MbCD treatment. In addition,
our results demonstrate for the ﬁrst time a partial association of
the thromboxane receptor with lipid rafts in platelets.
The importance of thromboxane-induced activation of human
platelets is underscored by the clinical beneﬁt of the blockade of
thromboxane synthesis with aspirin in patients with cardiovascu-
lar disease [1]. However, a variable percentage of aspirin-treated
patients are not fully protected with aspirin, an effect probably
related to an incomplete inhibition of thromboxane synthesis
[13,19]. In addition, residual thromboxane synthesis [23] could
cooperate with epinephrine to induce platelet aggregation [19],
thus reducing the effectiveness of aspirin treatment. These results
suggest that a better knowledge of the signal transductioneated resting platelets were lysated, ultracentrifuged in a gradient of sucrose, and
orresponding to lipid rafts were identiﬁed by the presence of CD36. The presence of
r the TXA2 receptor and results expressed as arbitrary units (AU). Images are
ith lipid rafts.
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new targets to improve aspirin therapy. Signaling through throm-
boxane receptor implies the participation of Gq and G13 but not of
Gi, and activation of PLCc [24]. Concerning platelet aggregation,
some authors have suggested that full aggregation of platelets in
response to thromboxane requires the participation of Gi activated
through the action of released ADP upon its P2Y12 receptor
[16,20,21], a result that is conﬁrmed in our study (Fig. 2A). In this
respect, the presence of both P2Y12 receptor [18] and Gi protein
[17] associated with lipids rafts in human platelets has been
previously described, as well as the importance of this location
for ADP-induced activation of platelets [17]. However, as demon-
strated in the present study other aspects of platelet responses to
thromboxane such as dense granule release and increase in cyto-
solic calcium are independent of ADP release or P2Y12 receptor
activation (Fig. 2B and C), in agreement with other authors
[16,20,21], and those ADP-independent responses are inhibited
by lipid raft disruption (Fig. 2D and E). In the present study, we
present evidence of the importance of the association of the throm-
boxane receptor with lipid rafts: (1) Disruption of lipid rafts with
MbCD reduced platelet aggregation induced with U46619 and
IBOP, two structurally different analogs of thromboxane (Fig. 1A);
(2) MbCD treatment also reduced aIIbb3 activation and P-selectin
exposure (Fig. 1B); (3) cytoplasmic calcium increases and dense
granule secretion, which are platelets responses to thromboxane
independent of P2Y12 signaling (Fig. 2B and C), were also signiﬁ-
cantly inhibited by cholesterol depletion (Figs. 2D and E); and (4)
The thromboxane receptor appears associated, at least partially,
with lipid rafts (Fig. 3). These results demonstrated, for the ﬁrst
time, that the association of the thromboxane receptor with lipid
rafts is relevant for the agonistic effect of thromboxane in human
platelets.
The presence of TXA2 receptor associated with lipid rafts has
been demonstrated in other cell types [8,9]. Our results demon-
strated that in resting platelets only a percentage (39.5%) of throm-
boxane receptor is associated with lipid rafts, while a greater
proportion is allocated outside of these structures. However, the
presence of the thromboxane receptor associated with lipid rafts
seems to be a key factor of its action. An interesting concern is
the role of the main pool of TXA2 receptor not associated with lipid
rafts in resting platelets. In preliminary results in our laboratory
we have observed that after platelet activation with different ago-
nists, the proportion of TXA2 receptor associated with lipid rafts
increased dramatically (results not shown), an effect clearly
reduced in MbCD treated platelets. We could speculate that the
incorporation of TXA2 receptor to lipid rafts after platelet activa-
tion could play an important role in platelet responses to TXA2.
The existence of two splice variants of thromboxane A2 receptors,
TPa and TPb has been reported in humans, although the dominant
form expressed in human platelets seems to be TPa [25]. We have
not performed experiments to detect the speciﬁc isoform of TXA2
receptor that is incorporated into lipid rafts. In a recent report by
Ibrahim et al. [9] described that activation of prostacyclin receptors
induced polymerization with thromboxane receptors and redistri-
bution to rafts in COS-7 cells, in a process related with cAMP levels.
Interestingly, we have previously described that in patients with
acute coronary syndrome treated with aspirin, activation of epi-
nephrine receptors increased the platelet response to arachidonic
acid [19]. These results suggest that epinephrine could also pro-
mote dimerization of TXA2 receptors, although this point requires
more investigations.
The presence of the ﬁbrinogen receptor integrin aIIbb3 associ-
ated with the lipid rafts is at the present a controversial issue
[22,26]. Our results show that disruption of lipid rafts strongly
inhibited U46119-induced aIIbb3 activation (Fig. 1B). More
investigations are required to deﬁne the role of the possible asso-ciation of aIIbb3 with lipid rafts in thromboxane-stimulated
platelets.
In conclusion, our results shown that association of a percent-
age of the thromboxane receptor with lipid rafts is a key factor
for platelet responses to thromboxane.Disclosure
None.
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